Literature DB >> 27893436

Carbon nanotubes as carriers of Panax ginseng metabolites and enhancers of ginsenosides Rb1 and Rg1 anti-cancer activity.

Mohamed H Lahiani1, Souzan Eassa2, Charlette Parnell3, Zeid Nima4, Anindya Ghosh3, Alexandru S Biris4, Mariya V Khodakovskaya1,5.   

Abstract

A major benefit to nanomaterial based-medicine is the ability to provide nanosized vehicles for sporadic metabolites. Here, we describe how the conjugation of valuable ginseng secondary metabolites (ginsenoside Rb1 or Rg1) with carbon nanotubes (CNT) can enhance their anti-proliferative and anti-cancer effects. Ginsenoside-CNT conjugate (Rb-CNT or Rg-CNT) permitted the ginsenosides to be used at a low dose, yet achieve a higher incidence of cancer killing. We were able to demonstrate that the ginsenoside-CNT conjugate can decrease cell viability up to 62% in breast cancer cells (MCF-7) and enhance antiproliferation of drug-resistant pancreatic cancer cells (PANC-1) by 61%. The interaction of the ginsenoside-CNT conjugate with breast cancer cells was studied using Raman Spectroscopy mapping. Total transcriptome profiling (Affymetrix platform) of MCF-7 cells treated with the ginsenoside-CNT conjugate shows that a number of cellular, apoptotic and response to stimulus processes were affected. Therefore, our data confirmed the potential use of CNT as a drug delivery system.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27893436     DOI: 10.1088/0957-4484/28/1/015101

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  5 in total

1.  MiR-23a targets RUNX2 and suppresses ginsenoside Rg1-induced angiogenesis in endothelial cells.

Authors:  Xiao-Dong Wu; Ting Guo; Li Liu; Chao Wang; Kun Zhang; Han-Qiang Liu; Feng Wang; Wen-Dong Bai; Meng-Yao Zhang
Journal:  Oncotarget       Date:  2017-07-22

Review 2.  Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment.

Authors:  Manuela Curcio; Annafranca Farfalla; Federica Saletta; Emanuele Valli; Elvira Pantuso; Fiore Pasquale Nicoletta; Francesca Iemma; Orazio Vittorio; Giuseppe Cirillo
Journal:  Molecules       Date:  2020-04-30       Impact factor: 4.411

3.  Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway.

Authors:  Yan-Long Tang; Cheng-Gui Zhang; Heng Liu; Yue Zhou; Ya-Ping Wang; Yuan Li; Yan-Jun Han; Cui-Li Wang
Journal:  Med Sci Monit       Date:  2020-02-10

Review 4.  Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Authors:  Hong Wang; Yu Zheng; Qiang Sun; Zhen Zhang; Mengnan Zhao; Cheng Peng; Sanjun Shi
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

Review 5.  Therapeutic Potential of Pien-Tze-Huang: A Review on Its Chemical Composition, Pharmacology, and Clinical Application.

Authors:  Lili Huang; Yiping Zhang; Xiaoqin Zhang; Xiuping Chen; Yitao Wang; Jinjian Lu; Mingqing Huang
Journal:  Molecules       Date:  2019-09-09       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.